Eyepoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week Low on Analyst Downgrade

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) reached a new 52-week low during trading on Monday after Jefferies Financial Group lowered their price target on the stock to $8.00. Jefferies Financial Group currently has a buy rating on the stock. Eyepoint Pharmaceuticals traded as low as $3.95 and last traded at $4.87, with a volume of 52110886 shares traded. The stock had previously closed at $14.75.

Other analysts have also recently issued research reports about the stock. Guggenheim restated a “buy” rating and set a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Monday. Royal Bank Of Canada lowered their price target on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Friday, July 17th. Finally, Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.33.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Jefferies lowered its price target to $8 but maintained a “buy” rating, implying substantial upside from the reported trading level. Chardan Capital also reaffirmed its “buy” rating with a $65 target. Benzinga analyst ratings
• Positive Sentiment: EyePoint said DURAVYU showed potentially favorable treatment-burden, supplement-free-rate, safety, and anatomic-control results through Week 56. In an ad hoc analysis excluding an asymmetric group of patients with unrelated vision loss, the drug was non-inferior to aflibercept. EyePoint LUGANO trial announcement
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating, indicating that the firm has not changed its cautious view despite the wide range of analyst price targets. Benzinga JPMorgan rating
• Neutral Sentiment: The stock was briefly halted for pending news, highlighting the market significance of the clinical update. A second pivotal Phase 3 trial remains important for determining DURAVYU’s regulatory and commercial prospects.
• Negative Sentiment: DURAVYU failed to achieve the primary endpoint in the full LUGANO dataset, despite EyePoint’s explanation that a 4% asymmetric cohort of nine patients with unrelated vision loss affected the result. The failure raises uncertainty about the drug’s approval prospects and the value of EyePoint’s pipeline. Reuters EyePoint trial report
• Negative Sentiment: Cantor Fitzgerald downgraded Eyepoint from “overweight” to “neutral,” while reports described the stock as approaching multi-month lows following the wet AMD trial setback. MSN EyePoint trial coverage

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Stempoint Capital LP grew its stake in shares of Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after acquiring an additional 456,915 shares in the last quarter. Janus Henderson Group PLC raised its stake in Eyepoint Pharmaceuticals by 22.6% in the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Eyepoint Pharmaceuticals by 2,158.3% in the 1st quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock valued at $1,355,000 after purchasing an additional 100,447 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Eyepoint Pharmaceuticals by 58.4% in the 1st quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company’s stock valued at $465,000 after purchasing an additional 13,297 shares during the period. Finally, Commodore Capital LP acquired a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth approximately $36,414,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Trading Down 67.0%

The stock’s 50-day simple moving average is $13.10 and its 200-day simple moving average is $13.62. The stock has a market cap of $419.84 million, a price-to-earnings ratio of -1.30 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. On average, equities research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -3.6 earnings per share for the current year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.